Loading clinical trials...

COMPLETED

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray

NCT00897182•Alliance for Clinical Trials in Oncology

Summary

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment. PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.

Detailed Description

OBJECTIVES: * To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia. * To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations. OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Enrolled on CALGB acute myeloid leukemia (AML) treatment studies AND concurrently enrolled on Leukemia Tissue Bank Protocol CALGB-9665
•Short-term or long-term survivor
•Bone marrow and/or peripheral blood obtained at diagnosis
•Leukemia is one of the following cytogenetic subtypes:
•* t(8;21)
•* t(15;17)
•* inv(16)

Locations (2)

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States

Wayne Memorial Hospital, Incorporated

Goldsboro, North Carolina, United States

Key Dates

Start Date

May 1, 2008

Primary Completion Date

March 1, 2014

Completion Date

March 1, 2014

Last Updated

July 4, 2016

Enrollment

ACTUAL participants

Conditions

Leukemia

Interventions

microarray analysis

GENETIC

polymerase chain reaction

GENETIC

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

NCT06311227

Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 4, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Inclusion Criteria

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

U69-CART-Cells For R/R T-ALL